Torii Pharmaceutical Co Ltd
TSE:4551
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Torii Pharmaceutical Co Ltd
Total Receivables
Torii Pharmaceutical Co Ltd
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Torii Pharmaceutical Co Ltd
TSE:4551
|
Total Receivables
¥27.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
1%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Total Receivables
¥757.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
4%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Total Receivables
¥696B
|
CAGR 3-Years
25%
|
CAGR 5-Years
21%
|
CAGR 10-Years
9%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Total Receivables
¥570.3B
|
CAGR 3-Years
10%
|
CAGR 5-Years
8%
|
CAGR 10-Years
4%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Total Receivables
¥443.1B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
12%
|
CAGR 10-Years
11%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Total Receivables
¥792.1B
|
CAGR 3-Years
20%
|
CAGR 5-Years
17%
|
CAGR 10-Years
8%
|
|
Torii Pharmaceutical Co Ltd
Glance View
Torii Pharmaceutical Co., Ltd. engages in the manufacturing and marketing of pharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 560 full-time employees. The company went IPO on 2013-10-01. The Company’s main product categories include oral pruritus improving agents, proteolytic enzyme inhibitors, hyperkalemia improving agents, topical adrenocortical hormones, allergen immunotherapy for cedar pollinosis, allergen immunotherapy for mite allergy, active viable bacterial preparations, uterine contraction inhibitors in premature birth and others. The Company’s main products include Remitch, Riona tablets, Keixalate, Yulinome tablets, Antebate, Locoid, Zefnate, Sida Torengi pollen sublingual solution, Miticure mite sublingual tablet, Biosley, Magcent and others.
See Also
What is Torii Pharmaceutical Co Ltd's Total Receivables?
Total Receivables
27.8B
JPY
Based on the financial report for Jun 30, 2025, Torii Pharmaceutical Co Ltd's Total Receivables amounts to 27.8B JPY.
What is Torii Pharmaceutical Co Ltd's Total Receivables growth rate?
Total Receivables CAGR 10Y
1%
Over the last year, the Total Receivables growth was 0%. The average annual Total Receivables growth rates for Torii Pharmaceutical Co Ltd have been 10% over the past three years , 10% over the past five years , and 1% over the past ten years .
